<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In heavily pre-treated patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC), further chemotherapy has not demonstrated efficacy </plain></SENT>
<SENT sid="1" pm="."><plain>Panitumumab is indicated as monotherapy treatment of epidermal growth factor receptor (EGFR)-expressing, Kirsten (K)-<z:mp ids='MP_0011356'>RAS</z:mp> <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> after failure of fluoropyrimidine-, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>- and irinotecan-containing regimens </plain></SENT>
<SENT sid="2" pm="."><plain>However, panitumumab has not been specifically evaluated in patients following failure of a bevacizumab-containing regimen </plain></SENT>
<SENT sid="3" pm="."><plain>One female and two male patients with mCRC presented with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> recurrence in the para-aortic lymph nodes, the liver and the local presacral lymph nodes, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The patients were confirmed to have K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:mp ids='MP_0002169'>wild-type</z:mp>-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Following the failure of bevacizumab-containing chemotherapy regimens, <z:hpo ids='HP_0000001'>all</z:hpo> three patients received panitumumab monotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Panitumumab was well-tolerated </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients responded to panitumumab monotherapy in this late-stage setting </plain></SENT>
<SENT sid="8" pm="."><plain>This patient series suggests that panitumumab can improve patient outcomes and may be an alternative treatment option in patients with mCRC who have received prior treatment with bevacizumab plus chemotherapy </plain></SENT>
</text></document>